Physician profile
Gerald Calegan
NPI 1902873516
$399,897.21
in general payments reported to CMS, 2019-2025
62 companies · $59K in 2025
The $59K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $40K · 2021: $54K · 2022: $34K · 2023: $77K · 2024: $57K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Food and Beverage: $28K · Travel and Lodging: $15K · Consulting Fee: $12K · Education: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,591.10 |
| Food and Beverage | $27,823.30 |
| Travel and Lodging | $15,396.94 |
| Consulting Fee | $12,173.00 |
| Education | $515.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $226,074.15 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $78,584.62 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $18,778.35 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $13,473.40 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $12,440.49 | 2019-2022 | |
| Abbott Laboratories | $12,044.41 | 2020-2025 | Infinity, Proclaim |
| Amneal Pharmaceuticals LLC | $7,577.59 | 2019-2025 | Crexont, Rytary |
| Medtronic USA, INC. | $6,042.31 | 2019-2020 | |
| Medtronic, INC. | $5,591.07 | 2021-2023 | Sensight, Percept Pc Brainsense |
| Biogen, INC. | $1,147.08 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $1,130.45 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Novartis Pharmaceuticals Corporation | $1,061.47 | 2019-2025 | |
| Adamas Pharmaceuticals, INC. | $1,017.34 | 2019-2021 | |
| Mdd US Operations, LLC | $1,008.77 | 2019-2025 | Gocovri, Apokyn, Xadago |
| Pfizer INC. | $968.62 | 2019-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $880.36 | 2019-2022 | |
| Acorda Therapeutics, INC | $870.94 | 2019-2024 | Inbrija |
| Amgen INC. | $854.61 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $678.18 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Genzyme Corporation | $663.24 | 2019-2025 | |
| Argenx US, INC. | $656.22 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $583.20 | 2019-2025 | Hizentra |
| Lundbeck LLC | $580.82 | 2020-2025 | Vyepti, Rexulti |
| Ipsen Biopharmaceuticals, INC | $533.58 | 2019-2025 | Dysport |
| Alexion Pharmaceuticals, INC. | $528.25 | 2019-2025 | Ultomiris, Soliris |
| Grifols USA, LLC | $511.23 | 2019-2025 | Gamunex-C |
| Eisai INC. | $498.30 | 2019-2025 | |
| Kyowa Kirin, INC. | $434.23 | 2019-2024 | Nourianz |
| Emd Serono, INC. | $391.58 | 2020-2025 | Mavenclad |
| Horizon Therapeutics Plc | $387.83 | 2021-2023 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $373.98 | 2023-2025 | Rexulti, Nuedexta |
| Neurelis, INC. | $297.10 | 2020-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $288.61 | 2021-2025 | Xeomin, Ampyra, Inbrija |
| Genentech USA, INC. | $272.77 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Ge Healthcare | $266.95 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.95 | 2023-2025 | Hyqvia, Gammagard |
| Biohaven Pharmaceuticals, INC. | $222.19 | 2021 | |
| Tg Therapeutics, INC. | $219.40 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $207.90 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $197.67 | 2022 | |
| Saol Therapeutics INC. | $192.87 | 2020 | |
| Revance Therapeutics, INC. | $176.12 | 2024-2025 | Daxxify |
| Sk Life Science, INC. | $145.59 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $126.51 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $124.06 | 2019-2021 | |
| Janssen Biotech, INC. | $101.10 | 2025 | |
| Janssen Pharmaceuticals, INC | $85.57 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $60.21 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $43.16 | 2023 | Trudhesa |
| Boston Scientific Corporation | $40.31 | 2024 | |
| Springworks Therapeutics, INC. | $31.18 | 2025 | Gomekli |
| Vertical Pharmaceuticals, LLC | $30.65 | 2020 | |
| Upsher-Smith Laboratories LLC | $24.30 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.83 | 2020 | |
| Averitas Pharma INC. | $14.62 | 2024 | Qutenza |
| Zyla Life Sciences, INC. | $14.20 | 2020 | |
| Axsome Therapeutics, INC. | $13.84 | 2025 | Symbravo |
| Azurity Pharmaceuticals, INC. | $13.75 | 2024 | Horizant |
| Currax Pharmaceuticals LLC | $13.61 | 2020 | |
| Tanabe Pharma America, INC. | $13.44 | 2022 | |
| Sumitomo Pharma America, INC. | $13.14 | 2023 | Aptiom |
| Insightec,INC | $11.94 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Calegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.